Avycaz FDA Approval History
FDA Approved: Yes (First approved February 25, 2015)
Brand name: Avycaz
Generic name: avibactam and ceftazidime
Dosage form: Injection
Company: AbbVie Inc.
Treatment for: Intraabdominal Infection, Urinary Tract Infection, Pneumonia
Avycaz (avibactam and ceftazidime) is a next generation, non-β lactam β-lactamase inhibitor and third-generation, antipseudomonal cephalosporin antibiotic combination for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.
Development timeline for Avycaz
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.